QIAGEN N.V. (QGEN)
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company?
QGEN Stock Likely to Gain From Innovation Amid Competition
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain QIAGEN Stock in Your Portfolio Now
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Unlocking Qiagen (QGEN) International Revenues: Trends, Surprises, and Prospects
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Qiagen N.V. (QGEN) Q2 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants John Gilardi - Investor Relations Thierry Bernard - Chief Executive Officer and Managing Director Roland Sackers - Chief Financial Officer and Managing Director Conference Call Participants Catherine Schulte - Baird Michael Ryskin - Bank of America Jack Meehan - Nephron Research Dan Arias - Stifel Odysseas Manesiotis - Berenberg Bank Douglas Schenkel - Wolfe Research Patrick Donnelly - Citi Matthew Sykes - Goldman Sachs Daniel Leonard - UBS Falko Friedrichs - Deutsche Bank Curtis Moiles - BNP Paribas Daniel Brennan - TD Cowen Operator Ladies and gentlemen, thank you for standing by.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
